Adherium posts 51% monthly RPM revenue surge as Hailie platform gains commercial traction
Adherium Limited has reported a 51% month-on-month increase in Remote Patient Monitoring (RPM) revenue, climbing from A$68,000 in December 2025 to A$103,000 in February 2026. The Adherium Hailie Smartinhaler Sales Growth demonstrates accelerating commercial momentum as the company scales its recurring revenue model across the US respiratory healthcare market.
The company’s January-February 2026 combined RPM revenue of A$198,000 has already surpassed the entire Q2 FY26 total of A$171,000, with one month still remaining in the current quarter. Adherium (ASX: ADR) scaled its RPM sales from zero at the start of calendar year 2025 to its current run-rate, supported by investment in the Adherium Care Team and commercial infrastructure.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
Device shipments and activations accelerate in early CY2026
Operational metrics underpinning the revenue growth show cumulative RPM device shipments increased 43% in the first two months of CY2026, whilst cumulative device activations increased 53% over the same period. Strong December shipments successfully converted into activated patients, validating the effectiveness of the Adherium Care Team model.
| Metric | 31 December 2025 | 28 February 2026 | Growth |
|---|---|---|---|
| Cumulative RPM device shipments | 2,149 | 3,071 | +43% |
| Cumulative RPM device activations | 1,425 | 2,183 | +53% |
The high activation conversion rate supports confidence in scaling toward the company’s target of 10,000 RPM patients by the end of 2026. This validates the commercial infrastructure investment and demonstrates that shipped devices are being successfully onboarded into revenue-generating patient relationships.
What is Remote Patient Monitoring and why does it matter for Adherium?
Remote Patient Monitoring allows healthcare providers to track patient medication usage remotely via connected devices. In the US healthcare system, RPM generates recurring monthly revenue through billing codes reimbursed by Medicare and private insurance.
This model represents a strategic shift for Adherium from one-time device sales to predictable, recurring revenue streams. As the patient base scales, RPM creates potential for compounding growth with higher-quality revenue characteristics compared to traditional device sales.
New US reimbursement codes create billing efficiency tailwind
Two new CPT codes effective 1 January 2026 have materially improved billing efficiency and speed to revenue:
- CPT 99445 reduces the billing threshold from 16 days to 2 days of data per month, enabling patients to become revenue-generating faster
- CPT 99470 enables billing for shorter consultations (10-19 minutes) at approximately US$26 per patient per month
- CPT 99457 remains available for longer consultations exceeding 19 minutes at approximately US$52 per patient per month
The previous CPT 99454 code required at least 16 days of data per month to bill a patient. The new CPT 99445 code lowers this requirement to just 2 days, materially reducing the billing threshold and increasing the speed at which patients become billable.
Lower billing thresholds mean improved unit economics and faster cash conversion timing across the RPM patient base. These reimbursement tailwinds provide structural support for commercial growth throughout CY2026 as the Adherium Call Centre continues onboarding patients to the Hailie Platform.
Growing patient pipeline supports 10,000 RPM target
Adherium now has access to approximately 48,000 valid insurance-verified asthma patients with compatible devices through its Call Centre and partners including Allergy Partners. This pipeline represents significant runway for conversion and supports the scalability of the RPM model.
Management has reaffirmed confidence in achieving 10,000 RPM patients by the end of CY2026, with today’s sales update demonstrating the company is executing on this milestone.
CEO Dawn Bitz
“In a short space of time, we’ve scaled sales under our Remote Patient Monitoring model from zero at the start of 2025 to A$103k per month as at end February 2026… With the benefit of these initiatives and reimbursement tailwinds, we have strong confidence in delivering our previously announced target of 10,000 RPM patients by the end of 2026.”
The 48,000-patient pipeline, combined with proven activation conversion rates and improved billing efficiency, positions Adherium to continue scaling its recurring revenue base throughout the remainder of the year.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
Upcoming clinical data release could support payer engagement
The Intermountain Health iCARE Study data will be presented at the American Thoracic Society International Conference, scheduled for 15-20 May 2026. This data is expected to validate the Hailie Platform by highlighting positive health outcomes generated through increased medication adherence in asthma and COPD, two of the most economically burdensome health conditions in the United States.
Key dates and catalysts:
- 15-20 May 2026 – American Thoracic Society International Conference
- Data expected to demonstrate health outcomes and economic impact
- Company intends to use data for US payer/insurer engagement regarding value-based care contracts
Positive clinical and economic data could unlock larger payer contracts and accelerate institutional adoption of the Hailie platform. The combination of operational momentum, improving unit economics, and upcoming clinical validation positions Adherium Hailie Smartinhaler Sales Growth as a key metric for investors monitoring the company’s commercialisation progress through 2026.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving healthcare alerts the moment market-moving announcements hit the ASX.